Depression, a complex psychiatric disorder that affects∼ 15% of the population, has an
enormous social cost. Although the disorder is thought to be the outcome of gene …

Antidepressants are commonly used in the treatment of anxiety and depression, medical
conditions that affect∼ 17–20% of the population. The clinical effects of antidepressants …

Gene microarrays may enable the elucidation of neurobiological changes underlying the
pathophysiology and treatment of major depression. However, previous studies of …

A principal weakness of evidence‐based psychiatry is that it does not account for the
individual variability in therapeutic response among individuals with the same diagnosis …

Abstract Analysis of differentially expressed genes in the brain is a promising tool for
elucidating pathological mechanisms that lead to central nervous disorders. Stress is known …

The aim of our study was to analyze the differential expression of miRNAs in the brains of
BSE-infected cynomolgus macaques as a model for Creutzfeldt-Jakob disease (CJD) …

While antidepressant pharmacotherapy is an effective treatment of depression, it still is
hampered by a delayed time of onset of clinical improvement and a series of side effects …

Cholecystokinin (CCK) is a neurotransmitter in the brain closely related to anxiety. Of the two
CCK receptor subtypes, CCK2 receptors are most implicated in the control of anxiety-related …

G protein‐coupled receptors are important regulators of cellular signaling processes. Within
the large family of rhodopsin‐like receptors, those binding to biogenic amines form a …

Major depression is a highly prevalent, multidimensional disorder. Although several classes
of antidepressants (ADs) are currently available, treatment efficacy is limited, and relapse …